Streetbeat News

RDGL

Vivos Inc

https://www.radiogel.com/

CEO

James Katzaroff

Employees

Industry

Surgical and Medical Instrument Manufacturing

Open

0.11

Mkt cap

50M

Volume

849K

High

0.13

P/E Ratio

-12.09

52-wk high

0.26

Low

0.11

Div yield

N/A

52-wk low

0.05

Vivos Inc.'s IsoPet® Division has achieved significant growth in 2024, expanding its network of certified veterinary clinics across the U.S., marking new milestones in veterinary cancer care.

Portfolio Pulse from

December 26, 2024 | 1:45 pm

Vivos Therapeutics has announced a registered direct offering and concurrent private placement to raise up to $6.9 million. The offering includes the sale of shares and issuance of short-term warrants.

Portfolio Pulse from

December 23, 2024 | 2:45 pm

Vivos Inc. has launched its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, marking a significant advancement in cancer treatment. The trial has successfully treated five patients with cancerous lymph nodes.

Portfolio Pulse from

December 23, 2024 | 1:45 pm

Vivos Therapeutics has announced a $3.5 million registered direct offering, selling 709,220 shares at $4.935 each, under Nasdaq rules. This move is aimed at raising capital for the company, which specializes in treatments for sleep-related breathing disorders.

Portfolio Pulse from

December 23, 2024 | 1:15 pm

Vivos Therapeutics reported a strong Q3 with a 17% increase in revenue and reduced operating expenses, aiming for positive cash flow.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its Q3 2024 financial results on November 14, 2024, after market close. The company specializes in treatments for sleep-related breathing disorders.

Portfolio Pulse from

November 13, 2024 | 10:15 pm

Vivos Inc. has expanded its IsoPet Precision Radionuclide Therapy to include exotic animals. This expansion could potentially increase the company's market reach and revenue streams.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:31 pm

Insiders are buying shares of Pineapple Financial Inc. (NYSE:PAPL) and Vivos Inc. (OTC:RDGL), indicating confidence in these companies despite recent challenges. Pineapple Financial's CSO bought 2,000 shares after a wider-than-expected quarterly loss, while Vivos' CEO acquired 50,000 shares following an FDA application for human clinical trials.

Portfolio Pulse from Avi Kapoor

August 05, 2024 | 1:13 pm

Insiders are buying shares of Vivos Inc. (OTC:RDGL), Alset Inc. (NASDAQ:AEI), and GEE Group Inc. (NYSE:JOB), indicating their confidence in these companies. Vivos' CEO bought 50,000 shares, Alset's CEO acquired 20,312 shares, and GEE Group's Director purchased 300,000 shares.

Portfolio Pulse from Avi Kapoor

June 05, 2024 | 11:16 am

The FDA has granted Breakthrough Device Designation to Vivos Inc.'s RadioGel for treating solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer. RadioGel is an injectable brachytherapy device using yttrium-90 for localized radiation treatment. Vivos Inc. plans to expedite its IDE submission for human clinical trials in collaboration with the Mayo Clinic.

Portfolio Pulse from Javier Hasse

December 21, 2023 | 4:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.